Home | Survey | Payment| Talks & Presentations | Job Opportunities
Journals   A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Infectious Disease Information
1007-8134
2013 Issue 2
Protocol for diagnosis and treatment of human infection with influenza A(H7N9) virus(Edition 2,2013)
National Health and Family Planning Commission of the People’s Republic of China
..............page:65-67
Focus on emerging infectious diseases and conquer influenza A(H7N9) virus
WANG Yong-yi;LI Jun;ZHANG Ling-xia
..............page:68
Preliminary analysis of the features of 102 cases of human infection with influenza A(H7N9) virus in China
HAN Ming-feng;RAN Xian-gui *;ZHAO Feng-de;CHENG Guo-ling;SHEN Hui;WANG Rui-rui Department of Respiratory Medicine;Fuyang Second People’s Hospital;Fuyang Infectious Disease Clinical College;Anhui Medical University;Fuyang;Anhui 236015;China
..............page:68-70,81
China’s guideline on nosocomial infection prevention and control of viral hepatitis C
Nosocomial Infection Control Branch of Chinese Preventive Medicine Association
..............page:71-75
Recommendation on antiviral therapy for HBV/HCV-related hepatocellular carcinoma
Liver Cancer Study Group;Chinese Society of Hepatology;Chinese Medical Association
..............page:76-81
Correlation between antiviral efficacy and serum levels of Th1/Th2 cytokines in patients with chronic hepatitis C
GUO Dan-dan;ZHANG Yong-hong;MA Li-na;LIU Ya-li;LU Jun-feng;JIN Yi;HE Zhi-min;HUA Wei;ZHENG Yan-hong;CHEN Xin-yue * International Medical Department;Beijing You’an Hospital;Capital Medical University;Beijing 100069;China
..............page:103-107
Combination therapy of Anluohuaxian capsule and adefovir dipivoxil for patients with hepatitis B-related compensated cirrhosis
WANG Jian-guo;ZHANG Yun-hui Department of Infectious Diseases;Yiyang Fourth People’s Hospital;Yiyang;Hunan 413000;China
..............page:108-111
Correlation between HBV serum markers and HBV DNA in patients with chronic hepatitis B
SHEN Huan-jun;CHEN Jing-yin;ZHANG Zhong-wei;WEI Yao;JIA Li-hong;KANG Bi-bo;WANG Ping-zhong * PLA Center of Infectious Diseases;Tangdu Hospital;The Fourth Military Medical University;Xi’an;Shaanxi 710038;China
..............page:111-114
Interferon α-2b treatment for chronic hepatitis B complicated by type 2 diabetes mellitus
KANG Xi;WANG Fang Center of Liver Diseases;Hanzhong Infectious Diseases Hospital;Hanzhong;Shaanxi 723000;China
..............page:115-117
a de fu wei zuo you fa fan ke ni zong he zheng he gu ruan hua zheng bing li bao gao he wu zhen fen xi
yuan le zuo wang bai fang wang bing yuan han hui fang gao jun tang fang zuo li xue hua
..............page:117-119
Drug resistance of adefovir dipivoxil
FAN Zhen-ping;JI Ying-jie;QIN Li;XU Dong-ping;ZHANG Hai-yan;SHI Xue-min;WANG Xue-qin;CAI Shao-ping;BU Xin;HE Wei-ping;ZHANG Wen-jin * Liver Disease Diagnosis and Treatment Center for Military Staff;302 Hospital of PLA;Beijing 100039;China
..............page:119-122
Progress and clinical significance of HCV genotyping
GAO Li *;YANG Shao-min Laboratory Department;Yunnan AIDS Care Center;Yunnan Provincial Hospital of Infectious Diseases;Kunming;Yunnan 650301;China
..............page:122-125
Brief introduction to the key points of the 2011 AASLD’s practice guideline on treatment of genotype 1 chronic hepatitis C virus infection
XU Xiao-yuan;FAN Xiao-hong;SHAO Cui-ping Department of Infectious Diseases;Peking University First Hospital;Beijing 100034;China
..............page:82-84
Research progress of sofosbuvir and ABT-450,the newest direct-acting anti-HCV agents
ZENG Qing-lei;LI Yuan-yuan;WANG Fu-sheng * The Institute of Translational Hepatology;302 Hospital of PLA;Peking University;Beijing 100039;China
..............page:85-88,92
Recent advances in diagnosis,prevention and treatment of hepatitis E
ZHANG Jun;WU Ting;XIA Ning-shao * National Institute of Diagnostics and Vaccine Development in infectious diseases;Xiamen University;Xiamen;Fujian 361100;China
..............page:89-92
Development of direct-acting antiviral agents against HCV
SU Hai-bin Liver Transplantation and Research Center;302 Hospital of PLA;Beijing 100039;China
..............page:126-130
Factors affecting HBV gene mutations in chronic HBV-infected patients receiving nucleos(t)ide analogue therapy
ZHAO Pan;DAI Jiu-zeng;LIU Fang-fang;YAO Zeng-tao;LI Le;XIN Shao-jie;XU Dong-ping * Liver Failure Therapy and Research Center;302 Hospital of PLA;Beijing 100039;China
..............page:93-95,130
Identification of various entecavir-resistant HBV strains and analysis of the inhibitory efficacy of tenofovir disoproxil
LI Yan-le;LIU Yan;XU Zhi-hui;WANG Xiao;CHEN Li;DAI Jiu-zeng;YAO Zeng-tao;JIANG Ling;ZHANG Lian-feng *;XU Dong-ping * Department of Gastroenterology;the First Affiliated Hospital of Zhengzhou University;Zhengzhou;Henan 450000;China
..............page:96-99,107
Determination of peripheral blood natural killer cell subsets in patients with chronic HCV infection and analysis of its clinical significance
ZHANG Min;XU Xiang-sheng;QIN En-qiang;HU Jin-hua;TONG Jing-jing;DUAN Xue-zhang * Liver Transplantation Center;302 Hospital of PLA;Beijing 100039;China
..............page:100-102